



Published in final edited form as:

Clin Cancer Res. 2009 October 1; 15(19): 6208–6216. doi:10.1158/1078-0432.CCR-09-0592.

Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival

Jason A. Zell^{1,2,3}, Argyrios Ziogas^{1,2}, Natalia Ignatenko⁴, Jane Honda^{1,2}, Ning Qu⁵, Alexander S. Bobbs⁶, Susan L. Neuhausen^{1,2}, Eugene W. Gerner^{5,7}, and Hoda Anton-Culver^{1,2}

¹Department of Epidemiology, University of California, Irvine, California 92697

²Genetic Epidemiology Research Institute, University of California, Irvine, California 92697

³Chao Family Comprehensive Cancer Center, Department of Medicine, University of California, Irvine, California 92697

⁴Department of Cell Biology and Anatomy, College of Medicine, The University of Arizona, Tucson, Arizona 85724

⁵Gastrointestinal Cancer Program, Arizona Cancer Center, The University of Arizona, Tucson, Arizona 85724

⁶Graduate Program in Biochemistry and Molecular Biology, The University of Arizona, Tucson, Arizona 85724

⁷Cancer Prevention Pharmaceuticals, Tucson, Arizona 85740

Abstract

Purpose—Activity of ornithine decarboxylase (ODC), the first enzyme in polyamine synthesis, is required for normal growth and is elevated in many cancers, including colorectal cancer (CRC). We examined associations of the +316 *ODCI* single nucleotide polymorphism (SNP) with CRC-specific survival among CRC cases, and then investigated its functional significance in colon cancer cells.

Experimental Design—The study included 400 incident stage I-III CRC cases from the population-based UC Irvine Gene-Environment Study of Familial CRC (diagnosed 1994-1996 with follow-up through March 2008). The primary outcome was CRC-specific survival (CRC-SS) dependent on *ODCI* (rs2302615) genotype (GG vs. GA/AA). In human colon cancer cell lines, *ODCI* allele-specific binding of E-box transcription factors was determined via western blotting and chromatin immunoprecipitation (CHIP) assays. *ODCI* allele-specific promoter activity was determined using promoter constructs in combination with vectors expressing either the transcriptional activator c-MYC or the repressor MAD1.

Correspondence to: Jason A. Zell, Department of Epidemiology, 224 Irvine Hall, University of California, Irvine; Irvine, CA, 92697, USA. Phone 1-949-824-0520; Fax 1-949-824-1343; jzell@uci.edu.

Disclosure of Potential Conflict of Interest: Eugene W. Gerner has an ownership interest in Cancer Prevention Pharmaceuticals, LLC.

Statement of Translational Relevance: Excess polyamine formation has long been implicated in epithelial carcinogenesis, particularly colorectal carcinogenesis. Recently, a strategy involving inhibition of ornithine decarboxylase (ODC) activity (i.e., the rate-limiting enzyme of polyamine synthesis) has demonstrated remarkable efficacy in preventing recurrence of colorectal polyps in humans. Epidemiologic and experimental results from the present research demonstrate conditional regulation of polyamine homeostasis by genetic polymorphism in *ODCI*, and suggest a model in which the +316 *ODCI* SNP may be protective for colon adenoma recurrence and detrimental for survival after diagnosis of non-metastatic colorectal cancer. This information may be useful for determining colon cancer prognosis. By identifying patients at increased risk for cancer progression/recurrence, early implementation of tertiary prevention management strategies could be instituted. Additionally, this research may help to identify high-risk but otherwise optimally-treated locoregional colorectal cancer patients that would benefit from tertiary cancer prevention clinical trials.

Results—Genotype-specific survival differences were observed among CRC cases: compared to cases with *ODCI* GG genotype (HR=1.00, reference) the adjusted CRC-SS hazards ratio (HR) was 2.02 (1.17-3.50) for *ODCI* GA/AA cases ($P = 0.012$). In colon cancer cells, the *ODCI* SNP, flanked by two E-boxes, predicts *ODCI* promoter activity. The E-box activator c-MYC and repressors MAD1 and MAD4 preferentially bind to *ODCI* minor A-, compared to major G-, alleles in cultured cells.

Conclusions—These results have implications for conditional regulation of polyamine homeostasis and suggest a model in which the *ODCI* SNP may be protective for colon adenoma recurrence and detrimental for survival after colon cancer diagnosis.

Keywords

Polyamines; E-box transcription factors; colorectal cancer; survival

Introduction

Polyamines are small ubiquitous molecules involved in various processes, including transcription, RNA stabilization, ion channel gating and others (1). Ornithine decarboxylase (ODC), the first enzyme in polyamine synthesis, is essential for normal development and tissue repair in mammals but is down-regulated in most adult tissues (2). Multiple abnormalities in the control of polyamine metabolism and transport result in increased polyamine levels that can promote tumorigenesis in several tissues (3). Polyamine metabolism is up-regulated in intestinal epithelial tissues of humans with familial adenomatous polyposis (FAP) (4), a syndrome associated with high risk of colon and other cancers. FAP is caused by mutations in the adenomatous polyposis coli (*APC*) tumor suppressor gene, and we have shown that wild-type *APC* signaling downregulates *ODCI* expression in both human cells (5) and in a mouse model of FAP (6). Wild type *APC* expression leads to decreased expression of ODC, while mutant *APC* leads to increased expression of ODC. The mechanism of *APC*-dependent regulation of ODC involves E-box transcription factors, including the transcriptional activator c-MYC and the transcriptional repressor MAD1 (5,7). c-MYC was shown by others to regulate *ODCI* transcription (8). Several genes involved in polyamine metabolism are essential genes for optimal growth in most organisms, and are down-regulated in non-proliferating and/or adult cells and tissues (2). The polyamines influence specific cellular phenotypes, in part, by affecting patterns of gene expression, as reviewed elsewhere (9).

D, L- α -Difluoromethylornithine (DFMO), a selective ODC inhibitor, decreases *APC*-dependent intestinal tumorigenesis in mice (6). Oral DFMO administered daily to humans inhibits ODC enzyme activity and polyamine contents in a number of epithelial tissues (10-15). Recently, DFMO in combination with the non-steroidal anti-inflammatory drug (NSAID) sulindac, has been reported to markedly lower the adenoma recurrence rate among individuals with colonic adenomas when compared to placebos in a randomized clinical trial (16). We have associated a common SNP in the *ODCI* promoter, 316 nucleotides 3' of the transcription start site, with decreased risk of colon polyp recurrence especially in people who report using aspirin (7), and this finding has been confirmed by others (17,18). This SNP falls between two consensus E-box binding elements. Although the risk of adenoma recurrence based on *ODCI* genotype has been investigated previously, the effects of this SNP on clinical outcomes after CRC diagnosis are unknown.

In this report, we studied the association of the *ODCI* +316 SNP to CRC-specific mortality among CRC cases from a population-based study. Subsequently, using experimental models involving cultured colon cancer cells we investigated the functional significance of the *ODCI* SNP, as depicted in Figure 1. Previous work by our group and others has associated the ODC A-allele at +316 to reduced risk of colon polyp recurrence (7). Ornithine decarboxylase

+316 genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention (18). Visvanathan et al. (19) have reported results apparently at odds with our previous findings in colon carcinogenesis. Visvanathan and colleagues have associated the *ODC1* A-allele at +316 with increased risk of prostate cancer. Our earlier functional studies, using promoter reporter methods (7) showed that the repressor MAD1 could suppress the expression of the *ODC1* promoter in an allele-specific manner. However, no direct evidence for binding of E-box transcription factors to the *ODC1* promoter in an allele-specific manner has yet been reported. Consequently, we tested the hypothesis that both transcriptional activators and repressors might bind selectively to the *ODC1* promoter in an allele-specific manner. Such allele specific binding might explain the apparent discordant associations of this allele with both reduced risk of precancerous lesions, but increased risk of invasive cancer, based on differences in the expression of E-box transcriptional activators and repressors. For example, c-MYC is known to be expressed at low levels in normal intestinal epithelium, but at high levels in intestinal polyps, in a mouse model of intestinal carcinogenesis (20).

Materials and Methods

Epidemiologic Studies: *ODC1* +316 SNP Associations with CRC-Specific Survival

Study population—We studied incident cases of invasive CRC with stage I-III disease at presentation enrolled in the University of California, Irvine Gene-Environment Study of Familial Colorectal Cancer (21,22) during 1994-1996 with follow-up through March 2008. The parent study was designed to determine the incidence of HNPCC in a large, population-based cohort of colorectal cancer cases. Participants were identified through the population-based cancer registries of the Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control using the April 2008 data file. In the parent study (21), all subjects with CRC diagnosed at all ages in Orange County, CA, from 1994 to 1996 were ascertained. All subjects diagnosed in San Diego and Imperial Counties, CA, at ages <65 y between 1994 and 1995 were also ascertained. Cases were then contacted if they were eligible for the study (alive at the time ascertained and having a contact address) and if their physicians did not deny permission to contact. At the time of study entry, cases signed a consent form allowing for blood draws and the release of medical information. This study was approved by the UC Irvine Institutional Review Board (#93-257). Clinical and demographic data including vital status and follow-up were obtained through linkage to the regional cancer registry databases as previously described (21-23). Tumor grade was recorded according to standard convention: grade I-well differentiated, grade II-moderately differentiated, grade III-poorly differentiated, grade IV-undifferentiated. Tumor, node, metastasis (TNM) staging determination was derived from existing AJCC codes where available and conversion of extent of disease codes, as previously reported (24). Family history of cancer in a first-degree relative was ascertained by self-reporting during a telephone interview conducted at enrollment (23, 25). Twenty-two cases with hereditary non-polyposis colon cancer (HNPCC), as defined by Amsterdam criteria, were identified and excluded from the analysis. The median time from CRC diagnosis until study entry (i.e., date of family history interview) was 18 months (95% CI 12-32 months).

DNA extraction and *ODC1* +316 SNP genotyping—DNA was extracted from 2.0 mL red blood cell clot samples using the QIAGEN QIAamp DNA Midi or Mini Kits, (Qiagen) following the manufacturer's instructions. Genotyping of the *ODC1* (National Center for Biotechnology Information SNP database ID rs2302615) +316 SNP was conducted using oligonucleotide primers designed to amplify a 172-bp fragment containing the polymorphic base at +316 (Applied Biosystems, Foster City, CA). Allele-specific TaqMan probes were synthesized with different 5' labels (6-carboxyfluorescein or VIC) and the same 3' quencher dye (6-carboxytetramethylrhodamine) (26). Each PCR reaction (5 μ L total) contained 10 ng

of participant DNA, 30 pmol of each primer, 12.5 pmol of each TaqMan probe, and 1× TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), as previously reported (7,26).

Statistical analysis – population-based study—An estimated 1:1 ratio of *ODCI* GG genotype to *ODCI* GA/AA genotype was expected based on previous literature (7,17,18,26). 440 of 481 DNA samples were successfully genotyped. 41 cases (8.5%) resulted in an undetermined *ODCI* +316 genotype due to low DNA concentration and/or poor DNA quality, however no clinicopathologic differences were observed between the successfully genotyped and unsuccessfully genotyped cases. The final analytic cohort was restricted to 400 CRC cases with stage I-III disease. Comparisons of demographic, clinical, and pathologic variables among colon and rectal cases were done using Pearson chi-square statistic or Fisher's exact test for nominal variables and Student t-test for continuous variables. Colorectal cancer-specific survival was defined as mortality from CRC itself, and data censoring occurred in the following instances: alive at the end of follow-up, loss to follow-up, or death from any cause other than CRC. Overall survival (OS) was defined with mortality from any cause. Survival curves were constructed for colon and rectal cancer cases using the Kaplan-Meier method and analyzed with the log rank test for univariate analyses. Cox proportional hazards modeling was performed for all CRC cases, colon cancer cases, and rectal cancer cases using time since diagnosis to profile the adjusted risk of overall and CRC-specific death based on *ODCI* genotype. The effects of *ODCI* genotype on survival were analyzed in the Cox models with stratification for TNM stage at diagnosis and adjustment for the following covariates: age, gender, ethnicity, family history of CRC, tumor site within the colon, histologic subtype, treatment with surgery, radiation therapy, and chemotherapy. For covariates with categorical data, dummy coding was assigned (0 or 1) and each category was included in the multivariate models in comparison to the referent group. *ODCI* genotype was analyzed using the dominant model (GG vs. GA/AA) using dummy variables with GA/AA coded as 1 and GG as the referent group. Subset analyses were performed using the additive model for *ODCI* either as continuous variable 0, 1 and 2 test for trend, or using two dummy variables one for GA and one for AA with GG as the referent group. All analyses were conducted using SAS 9.2 statistical software (SAS Institute, Cary, NC). Statistical significance was assumed for a 2-tailed P value <0.05.

Experimental Studies: *ODCI* +316 SNP Regulation in Colon Cancer Cells

Cell culture—The human colon cancer cell lines HT29 and HCT116 were maintained in McCoy's 5A medium (Invitrogen, Carlsbad, CA). All media used were supplemented with 10% FBS plus 1% penicillin/streptomycin solution (Invitrogen, Carlsbad, CA). Cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂.

Genotyping assay—DNA samples from HT29 and HCT116 cells were subjected to a PCR-RFLP procedure to detect the polymorphic PstI site. Sequences were amplified by PCR, using the following primers: 5'- TCTGCGCTTCCCCATGGGGCT-3' and 5'- TTTCCCAACCCTTCG-3'. Each reaction contained – 1 µl DNA, 4 pmol of each primer, 12.5 µl 2× PCR PreMixes buffer “G” (EPICENTRE Biotechnologies, Madison, WI) and 0.5 unit of Taq DNA polymerase, in a final volume of 25 µl. The expected size of the PCR product was 351 bp. After amplification, 10-20 µl of the PCR product were digested with 10 units of PstI in 30 µl for 2 hours at 37°C. DNA from HT29 cells (GA), containing the PstI site, yielded two fragments of 156 and 195 bp.

Western blot analysis—Cells were harvested, lysed and proteins were separated on a 12.5% SDS-PAGE gel. Proteins were transferred by electrophoresis onto a Hybond-C membrane. The membrane was blocked with Blotto A (5% blocking grade dry milk in TTBS solution) and probed using 1:300 dilutions of primary antibodies (Santa Cruz Biotechnology, Santa Cruz,

CA) in Blotto A. Primary antibodies were incubated at 4°C overnight, followed by incubation with an appropriate HRP-tagged secondary antibody (1:1000 dilution) for 1 hour at room temperature. Chemiluminescent detection was conducted using ECL Western Detection reagent (Amersham Biosciences, Piscataway, NJ) and exposed on Biomax XAR film (Kodak).

Chromatin immunoprecipitation (CHIP)—CHIP assays were performed using a commercial kit, as recommended by the manufacturer (Upstate Biotech, Lake Placid, NY, USA). Briefly, cells were treated with 1% formaldehyde to crosslink DNA and proteins, and DNA-protein complexes were disrupted by sonication to lengths between 200 to 1000 bp. Lysates were diluted 10-fold with immunoprecipitation (IP) dilution buffer containing protease inhibitors. Antibodies for c-MYC, MAD1 and MAD4 (Santa Cruz Biotechnology, Santa Cruz, CA) were used to precipitate chromatin, while additional sample was left as a minus-antibody (-Ab) control. Samples were immunoprecipitated overnight at 4°C with rotation. Immune complexes were obtained by adding 60ul of salmon sperm DNA/protein A Agarose slurry and incubating for an hour at 4°C with rotation followed by gentle centrifugation (1000 rpm, 1 min). Protein A agarose pellets were washed with low salt buffer, high salt buffer, LiCl buffer and TE buffer. Then the complexes were eluted by adding 250 µl elution buffer (0.1M NaHCO₃, 1% SDS) twice, and DNA-protein crosslinks were reversed with 0.2 M NaCl by heating at 65°C for 4 hours for all samples, including the input DNA and -Ab DNA controls. DNA was resuspended in 30ul of ddH₂O. For visualization of PCR product and its size, standard PCR reactions were carried out. The sequences of *ODC1* primers used for PCR were 5'- CCTGGGCGCTCTGAGGT-3' (17mer) and 5'-AGGAAGCGGCGCCTCAA-3' (17mer). Quantitative real-time PCR was performed using TaqMan gene expression assays kit (Applied Biosystems, Foster City, CA) on an ABI7700 sequence detection system. Details for the computation of relative binding can be found on the manufacturer's web site (<http://www.appliedbiosystems.com/>).

Transient transfections—Transient transfections were performed using LipofectAMINE reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol, as detailed in the supplementary file. HCT116 and HT29 cells were transfected with 1 µg of pGL3-*ODC1*/A or pGL3-*ODC1*/G plasmids (7) along with 0.01 µg of Renilla-TK plasmid. The Renilla-TK plasmid was purchased from Promega (Madison, WI) and used as a transfection efficiency control in all promoter-reporter transfection experiments. For *MYC* experiments, *ODC1* pGL3-plasmids were co-transfected with either pcDNA 3.0 or CMV-*MYC* expression vector (OriGene, Rockville, MD). For *MAD1* experiments, the *ODC1* plasmids were co-transfected with either pcDNA 3.1 or pcDNA-*MAD1*. For *MYC* and *MAD1* co-transfection, *ODC1* promoter reporter constructs were prepared which contain the first 1.6 Kb of the *ODC1* gene cloned into a pGL3 vector. The constructs included E-box 1 (-485 to -480 bp) intact (wt E-box 1) or deleted (mut E-box 1). Additionally, both variants of the +316 *ODC1* SNP were used, creating a total of 4 different constructs. After 6 hours of incubation, cells were supplemented with complete medium containing 20% FBS and left to grow overnight. The next day after transfection 20% FBS-containing complete medium was replaced with 10% FBS-containing medium. 48 hours after transfection, cells were washed with PBS and lysed in Passive Lysis Buffer from the Dual Luciferase Assay kit (Promega, Madison, WI). Dual luciferase activities were measured using a Turner Designs TD-20/20 luminometer, as described by the manufacturer, and presented as relative luciferase units (RLU). Experiments were performed in triplicates and repeated at least 2 times.

Statistical analysis - experimental studies—For transient transfection experiments, two-sample *t*-tests were used (Microsoft Excel Microsoft Corp., Redmond, WA). The effect of *MYC* expression on *ODC1* allele-specific promoter activity was examined in HT29 colon cancer cells using *ODC1* promoter constructs differing by the presence of the first E-box

element: (a) wild type (wt) E-box1+316 G, (b) mutant (mut) E-box1 + 316 G, (c) wt E-box1 + 316 A, and (d) mut E-box1 + 316 A. For each promoter construct, two-sample *t*-tests were used to compare promoter activity between cells co-transfected with pcDNA3.0 plasmid versus those transfected with the CMV-*MYC* expression vector. Similarly, to examine the effect of *MAD1* expression on *ODC1* allele-specific promoter activity, two-sample *t*-tests were used to compare the effect of promoter activity in promoter constructs co-transfected with pcDNA3.1 plasmid versus those transfected with pcDNA-*MAD1* plasmid. Statistical significance was assumed for a 2-tailed *P* value <0.05.

Results

Epidemiologic Studies: Association of the *ODC1* +316 SNP with CRC-Specific Survival among Colon and Rectal Cancer Cases

A total of 400 stage I-III CRC cases identified from the UC Irvine CRC gene-environment study were used in the case-only analysis. Median follow-up duration was 11 years, 1 month. There were 252 (63%) colon cancer cases, 143 (36%) rectal cancer cases, and 5 (1%) CRC cases of unspecified location. Clinicopathologic data for colorectal cancer cases are shown in Table 1. Timing of radiation therapy was available for 60 cases (55 rectal and 5 colon cancer cases) of the 63 receiving radiation therapy. Thirteen (21.7%) received neoadjuvant (i.e. pre-surgery) radiation, 45 (75.0%) received adjuvant (i.e., post-surgery) radiation, and 2 (3.3%) received combination neoadjuvant and adjuvant radiation therapy. *ODC1* genotype distribution among all CRC cases was 52% GG, 41% GA, and 7% AA. There were no significant differences in *ODC1* genotype distribution (GG vs. GA/AA) by age, gender, ethnicity, family history, stage, site within the colorectum, histology, or tumor grade (Table 1). When analyzed by three genotypes (GG, GA, AA), *ODC1* genotype distribution by ethnicity revealed significant differences: Caucasian (351 cases: 54% GG, 40% GA, 6% AA, minor-A allele frequency = 26%), African-American (4 cases: 50% GG, 50% GA, 0% AA, minor-A allele frequency = 25%), Hispanics (20 cases: 55% GG, 45% GA, 0% AA, minor-A allele frequency = 23%), and Asians (23 cases: 30% GG, 44% GA, 26% AA, minor-A allele frequency = 48%) (*P* = 0.012). However, within each race *ODC1* genotype distribution was in Hardy-Weinberg equilibrium (Caucasians *P* = 0.51, African-Americans *P* = 0.51, Hispanics *P* = 0.19, Asians *P* = 0.54).

Of the 400 stage I-III CRC cases, 109 (27%) were deceased at the time of analysis. Forty-seven (43%) deaths occurred in cases carrying the *ODC1* GG genotype, compared to 62 (57%) deaths in cases with the AA/AG genotypes. Cause of death was available for 76 of the 109 deceased CRC cases. Fifty-nine (77%) CRC cases died as a result of CRC. A statistically significant improvement in CRC-specific survival was observed among CRC cases homozygous for the *ODC1* G-allele (10-year survival = 89%) compared to cases with at least one A-allele (*ODC1* GA/AA) (10-year survival = 81%; *P* = 0.011). CRC-specific survival analysis by stage revealed that significantly different survival differences were not observed for AJCC stage I (*P* = 0.055) or II (*P* = 0.61) CRC. However, among cases with stage III CRC the *ODC1* GG genotype was associated with improved 10-year CRC-specific survival: 75% compared to 60% for *ODC1* GA/AA genotype cases; *P* = 0.024 (Fig. 2). This difference was significant among rectal (10-year OS = 88% for *ODC1* GG vs. 75% for *ODC1* GA/AA; *P* = 0.041) but not colon cancer cases (10-year OS = 89% for *ODC1* GG vs. 84% for *ODC1* GA/AA; *P* = 0.11).

Among CRC cases, the CRC-specific survival estimates based on *ODC1* genotype after stratification for TNM stage at diagnosis and adjustment for age (years), gender, ethnicity, family history of CRC, tumor site within the colon, histologic subtype, treatment with surgery, radiation therapy, and chemotherapy were as follows: *ODC1* GG hazards ratio (HR) = 1.00 (referent), *ODC1* GA/AA HR = 2.02 (*P* = 0.021) (Table 2). In the additive model, adjusted CRC-specific survival estimates were as follows: *ODC1* GG hazards ratio (HR) = 1.00

(referent), *ODCI* GA HR = 1.95, *ODCI* AA HR = 2.25 (*P-trend* = 0.015). Subset multivariate CRC-specific survival analysis revealed that *ODCI* genotype was a significant prognostic factor among rectal (*ODCI* GA/AA HR=2.92, 95% CI 1.22-7.03 using *ODCI* GG as a referent) but not colon cancer cases (*ODCI* GA/AA HR=1.76, 95% CI 0.85-3.63 using *ODCI* GG as a referent). No significant associations with *ODCI* genotype and overall survival were detected in subset adjusted analyses of rectal, or colon cancer cases.

As noted above, the *ODCI* +316 genotype distribution differed across ethnicity. The observed mortality risk, other than by chance, likely reflects differences based on *ODCI* genotype, however the risk may be restricted to a particular ethnic group. Thus multivariate analyses were conducted among Caucasian colon cancer cases, to assess genotype-specific mortality risk within this single ethnic group. Among the 351 Caucasians, there were 52 CRC-related deaths. Multivariate CRC-specific survival analysis revealed that the *ODCI* SNP was an independent predictor of CRC-specific survival among Caucasian CRC cases after adjustment for the aforementioned relevant clinical variables. Compared to cases with *ODCI* GG genotype (HR=1.00, reference), the CRC-specific risk of death (HR) was 2.37 (1.33-4.23) for *ODCI* GA/AA genotype.

Experimental Studies: *ODCI* +316 SNP Regulation in Colon Cancer Cells

***ODCI* allele-specific binding of E-box transcription factors**—We evaluated the functional significance of the +316 *ODCI* SNP, located between two E-boxes (E-box 2 and 3 as depicted in Fig. 3, A). Each cell line genotype influences a consensus PstI restriction site in this region. Fig. 3, B shows that a polymerase chain reaction (PCR) product made from human colon HT29 cells was partially sensitive to PstI cutting, suggesting that these cells contained at least one *ODCI* A-allele. A PCR product made from human colon HCT116 cells using the same primers was insensitive to PstI action, implying that these cells contained only *ODCI* G-alleles. This result was confirmed by direct DNA sequencing (data not shown).

Expression of specific E-box binding proteins, including the transcriptional activator c-MYC and several transcriptional repressors in HT29 and HCT116 cells (e.g. MAD1 and MAD4), was established by Western blotting (Fig. 4, A). Chromatin immunoprecipitation (CHIP) analysis of the region surrounding +316 of the *ODCI* promoter was conducted, using antibodies directed against these proteins. As shown in Fig. 4, B, *ODCI* promoter-specific PCR products were synthesized from HT29 DNA obtained after immunoprecipitation of chromatin with antibodies directed against c-MYC, MAD1 or MAD4. PCR products synthesized from HCT116 DNA after similar chromatin immunoprecipitation were substantially reduced compared to those synthesized from HT29 DNA. Quantification of these results indicated that c-MYC, MAD1, and MAD4 binding to the *ODCI* SNP region was 4-14 times greater in HT29 cells, which contained one *ODCI*-A allele, compared to HCT116 cells, which contained only *ODCI*-G alleles (Supplemental Table).

***ODCI* allele-specific promoter activity**—We tested the hypothesis that +316 *ODCI* SNP influenced *ODCI* expression in a manner dependant on the expression of E-box activators and repressors. Transient co-transfection of colon cancer-derived HT29 cells was accomplished with *ODCI* allele-specific promoter constructs in combination with vectors expressing either the transcriptional activator *MYC* or the repressor *MAD1* (Fig. 5). The standard error bars shown reflect the variability in triplicate measurements within a single representative experiment, which has been replicated. The allele-specific promoter-reporters used in these experiments included all three E-boxes shown in Fig. 3, A. As shown in Fig. 5, A, *MYC* expression had the greatest stimulatory effect on promoters containing three consensus E-boxes and the *ODCI*-A allele (wt E-box1 +316 A, *P* = 0.0014). Deletion of the upstream E-box reduced promoter activity, but *MYC* expression continued to stimulate this activity (mut E-box1 +316 A, *P* =

0.0013). Substitution of a G for the A at the *ODCI* +316 SNP position reduced the ability of c-MYC to stimulate promoter activity even with an intact 5' flanking consensus E-box. Mutation of the 5' flanking consensus E-box in combination with the *ODCI*-G allele further reduced promoter activity

When *MAD1*, rather than *MYC*, was co-transfected with the *ODCI* allele-specific promoter reporters (Fig. 5, B), the repressor was only able to reduce the activity of the *ODCI* promoter which contained all three E-boxes and the wild-type +316 A-allele ($P = 0.027$). Deletion of the upstream E-box (mut E-box 1 +316A) significantly reduced the effect of *MAD1* on *ODCI* promoter activity. Substitution of G for A at the +316 position rendered promoters containing either two or three E-boxes unresponsive to *MAD1* suppression.

Discussion

In our population-based analysis of colorectal cancer cases with more than eleven years follow-up duration, we observed that the +316 *ODCI* SNP was associated with colorectal cancer specific survival (CRC-SS) among CRC cases, with a greater association observed among rectal cancer cases. A statistically significant increased risk of CRC-specific mortality was observed for *ODCI* GA/AA cases among rectal cancer cases, after stratification for stage and adjustment for age, gender, ethnicity, family history of CRC, tumor site, histology, treatment with surgery, radiation therapy, and chemotherapy.

The experimental data presented here provide insights into potential biologic mechanisms underlying our clinical observations. In colon cancer epithelial cells, we have shown that the *ODCI* +316 SNP is functionally significant, as evidenced by increased binding of E-box transcription factors to promoter elements containing A-, compared to G-, alleles. Both the activator c-MYC and the repressor *MAD1* show greater effects on promoter activity in reporter elements containing A- versus G- alleles. These results suggest allele-specific regulation of *ODCI* by E-box transcription factors. ODC protein enzyme activity is not apparently affected by the *ODCI* +316 SNP genotype, which we believe influences *ODCI* transcription.

In colon cells, we have shown that conditional expression of wild type *APC*, a gene expressed in normal colonic mucosa, suppresses *MYC*, and increases *MAD1*, expression (5). Further, we have reported that wild type *APC* can regulate *ODCI* promoter activity in a manner dependent on the +316 SNP (7). Wild type *APC* is expressed in the apparently normal colonic mucosa of individuals not afflicted with FAP, while the majority of sporadic colon adenomas show evidence of mutated or deleted *APC* (27). *MYC* is expressed at low levels in normal intestinal mucosa but is increased in intestinal adenomas of *APC*^{Min/+} mice. Conditional knockout of intestinal epithelial *MYC* expression suppresses intestinal tumorigenesis in *APC*^{Min/+} mice (20). As described above, previous work by our group (7) and others (18) demonstrated a protective role for the *ODCI* A-allele, especially in aspirin users, against recurrence of colon polyps in clinical prevention trials. However, in the population-based study presented here, the *ODCI* A-allele was associated with poor survival. This apparent contradiction may be explained by the results shown here, which indicate that both E-box activators and repressors bind the *ODCI* A-allele selectively. If the transformed epithelium begins to express E-box activators (such as c-MYC), then cancer progression may be more likely to occur in individuals with the *ODCI* A-allele genotype. Our results for risk of colon cancer-specific mortality are consistent with those of others showing that risk of prostate cancer may be associated with the *ODCI* A-allele among specific individuals as the result of gene environment interactions (19,28). Such colon cancer progression could be due to enhanced polyamine synthesis, as has been demonstrated already for prostate cancer (15).

Our finding that a factor, such as the *ODCI* SNP, may have both promoting and inhibiting effects on carcinogenesis is not unique. For example, transforming growth factor-beta (TGF- β) has diverse roles in carcinogenesis and cancer progression (29-31). TGF- β in untransformed cells inhibits cell proliferation and induces apoptosis. Yet, it is overexpressed in all human tumors and is associated with late cancer progression, specifically tumor invasion and metastasis. A single study by Matsubara et al. reporting *ODCI* activity in human colorectal tumors demonstrated that high levels of *ODCI* expression was significantly associated with improved survival (32). This suggests that, although *ODCI* overexpression promotes the formation of human colorectal adenomas, it is possible that in established lesions, *ODCI* overexpression causes enhanced proliferation and is associated with improved response to anti-proliferative treatments. However, that study did not include stratification by *ODCI* genotype, so it is not known if these effects are independent of *ODCI* genotype. Population differences between the Matsubara et al. study and ours could account for the differences. For example, the former study included few rectal cancers (5%), whereas our study cohort was comprised of a substantial proportion of rectal cancer cases (36%). This difference is not trivial, since the observed associations of the *ODCI* SNP with CRC-SS were greater for rectal compared to colon cancer cases. The Matsubara et al. study was comprised of 63.5% females compared to our study which included 41% females. Furthermore, the distribution by race/ethnicity differs substantially between the two studies. Additionally, chance variation could explain why our findings differ from the prior analysis.

The observed associations of the *ODCI* +316 SNP with CRC-specific mortality were greatest among rectal cancer cases. Among all CRC cases, particularly strong effects were observed for Caucasians. Similar to other reports, the *ODCI* +316 SNP allele frequency differs considerably by ethnicity (28). When we limited the survival analysis to Caucasians only (i.e., the only ethnic group with adequate power for such analyses), the associations of the *ODCI* +316 SNP were significant, and of greater magnitude than the estimates observed for the entire cohort.

The epidemiologic study shares limitations of other population-based analyses, including lack of data on comorbid conditions, performance status, and particular chemotherapeutic regimens utilized. Additionally, the tissue biopsy samples obtained from participants of the UC Irvine Gene-Environment Study of Familial Colorectal Cancer are paraffin-embedded specimens and therefore cannot be used for accurate assessment of tissue polyamine quantification by high performance liquid chromatography (HPLC). There is also the potential for selection bias, favoring a relatively healthy group of CRC survivors, since there was a median 18month delay from the time of CRC diagnosis until study enrollment. Other factors affecting polyamine metabolism that were not accounted for in the present study may explain our observations. For example, aspirin activates polyamine acetylation and export and works with the *ODCI* A-allele to reduce cell and tissue polyamine contents (2,7,33). Our experimental findings are limited to the effects of the *ODCI* +316 SNP in two colon cancer cell lines. Thus validation of our findings is warranted.

In summary, we have observed clinical consequences of the *ODCI* +316 SNP on CRC-specific mortality among CRC cases. Additionally, we have further established the functional significance of the *ODCI* +316 SNP in the c-MYC- and MAD1-dependent transcription of this gene in human colon cancer cells. Together, these experimental and epidemiologic findings suggest a role for the *ODCI* SNP in progression of CRC distinct from its previously reported role in progression to colon adenomas. Provided that our results are validated in future research, these novel findings may contribute to our ability to assess risk of CRC progression and may direct patient-specific pharmacogenetic management, surveillance monitoring, and inform novel targeted approaches to secondary and tertiary CRC prevention.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Tom O'Brien for the *ODCI* allele specific promoter reporters.

Financial support: This work was supported by grants from the National Institutes of Health (USA), CA72008 (EWG), CA78134 (HAC), CA78285 (HAC), CA95060 (EWG), K23 CA133142 (Zell), and L30 CA130160 (Zell)

The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N01-PC-54404 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement 1U58DP00807-01 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred.

References

- Wallace HM. The physiological role of the polyamines. *Eur J Clin Invest* 2000;30:1–3. [PubMed: 10619994]
- Gerner EW, Meyskens FL. Polyamines and cancer: Old molecules, new understanding. *Nature Reviews Cancer* 2004;4:781–92.
- Thomas T, Thomas TJ. Polyamine metabolism and cancer. *JCell MolMed* 2003;7:113–26.
- Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. *Cancer Research* 1997;57:199–201. [PubMed: 9000553]
- Fultz KE, Gerner EW. APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. *MolCarcinog* 2002;34:10–8.
- Erdman SH, Ignatenko NA, Powell MB, et al. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. *Carcinogenesis* 1999;20:1709–13. [PubMed: 10469614]
- Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100:7859–64. [PubMed: 12810952]
- Bellofernandez C, Packham G, Cleveland JL. The Ornithine Decarboxylase Gene Is A Transcriptional Target of C-Myc. *Proceedings of the National Academy of Sciences of the United States of America* 1993;90:7804–8. [PubMed: 8356088]
- Childs AC, Mehta DJ, Gerner EW. Polyamine-dependent gene expression. *Cell Mol Life Sci* 2003;60:1394–406. [PubMed: 12943227]
- Love RR, Carbone PP, Verma AK, et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. *J Natl Cancer Inst* 1993;85:732–7. [PubMed: 8478959]
- Gerner EW, Garewal HS, Emerson SS, Sampliner RE. Gastrointestinal Tissue Polyamine Contents of Patients with Barretts-Esophagus Treated with Alpha-Difluoromethylornithine. *Cancer Epidemiology Biomarkers & Prevention* 1994;3:325–30.
- Meyskens FL, Emerson SS, Pelot D, et al. Dose De-Escalation Chemoprevention Trial of Alpha-Difluoromethylornithine in Patients with Colon Polyps. *Journal of the National Cancer Institute* 1994;86:1122–30. [PubMed: 8028034]
- Meyskens FL, Gerner EW, Emerson S, et al. Effect of alpha-difluoromethylornithine on Rectal Mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. *Journal of the National Cancer Institute* 1998;90:1212–8. [PubMed: 9719082]

14. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr. Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. *J Natl Cancer Inst* 2001;93:57–9. [PubMed: 11136843]
15. Simoneau AR, Gerner EW, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. *Cancer Epidemiol Biomarkers Prev* 2008;17:292–9. [PubMed: 18268112]
16. Meyskens FL, McLaren CE, Pelot D, Fujikawa S, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. *Cancer Prevention Research* 2008;1:32–8. [PubMed: 18841250]
17. Barry ELR, Baron JA, Bhat S, et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. *Journal of the National Cancer Institute* 2006;98:1494–500. [PubMed: 17047198]
18. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. *Clin Cancer Res* 2008;14:2303–9. [PubMed: 18413818]
19. Visvanathan K, Helzlsouer KJ, Boorman DW, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. *Journal of Urology* 2004;171:652–5. [PubMed: 14713779]
20. Ignatenko NA, Holubec H, Besselsen DG, et al. Role of c-Myc in intestinal tumorigenesis of the *ApcMin/+* mouse. *Cancer Biol Ther* 2006;5:1658–64. [PubMed: 17106247]
21. Peel DJ, Ziogas A, Fox EA, et al. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. *J Natl Cancer Inst* 2000;92:1517–22.
22. Zell JA, Ignatenko NA, Yerushalmi HF, et al. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. *International Journal of Cancer* 2007;120:459–68.
23. Zell JA, Honda J, Ziogas A, Anton-Culver H. Survival after Colorectal Cancer Diagnosis is Associated with Colorectal Cancer Family History. *Cancer Epidemiol Biomarkers Prev* 2008;17:3134–40. [PubMed: 18990755]
24. Le H, Ziogas A, Lipkin SM, Zell JA. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. *Cancer Epidemiol Biomarkers Prev* 2008;17:1950–62. [PubMed: 18708384]
25. Ziogas A, Anton-Culver H. Validation of family history data in cancer family registries. *Am J Prev Med* 2003;24:190–8. [PubMed: 12568826]
26. Guo YJ, Harris RB, Rosson D, Boorman D, O'Brien TG. Functional analysis of human ornithine decarboxylase alleles. *Cancer Research* 2000;60:6314–7. [PubMed: 11103791]
27. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. *Carcinogenesis* 2000;21:1935–40. [PubMed: 11062151]
28. O'Brien TG, Guo Y, Visvanathan K, et al. Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups. *Molecular Carcinogenesis* 2004;41:120–3. [PubMed: 15378650]
29. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. *Nature Genetics* 2001;29:117–29. [PubMed: 11586292]
30. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. *Biochimica et Biophysica Acta* 2007;1775:21–62. [PubMed: 16904831]
31. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100:8621–3. [PubMed: 12861075]
32. Matsubara N, Hietala OA, Gilmour SK, et al. Association between high levels of ornithine decarboxylase activity and favorable prognosis in human colorectal carcinoma. *Clinical Cancer Research* 1995;1:665–71. [PubMed: 9816030]
33. Babbar N, Gerner EW, Casero RA Jr. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. *Biochem J* 2006;394:317–24. [PubMed: 16262603]

Abbreviations

ODC

ornithine decarboxylase

SNP

single nucleotide polymorphism




Fig. 1. Schema depicting the proposed differential effects of polyamine regulation by MAD1 and c-MYC on the *ornithine decarboxylase-1 (ODC-1)* +316 minor A-allele. Effects of the ODC inhibitor DFMO (difluoromethylornithine) are also shown.




Fig. 2. Kaplan-Meier colorectal cancer (CRC) specific survival rate estimates for cases with stage III CRC, stratified by *ornithine decarboxylase 1* (*ODC1*) +316 genotype. Includes cases from the University of California Irvine Gene-Environment Study of Familial CRC diagnosed during 1994-1996 with follow-up through March 2008; *ODC1* GG (64 cases, 15 CRC-specific deaths), *ODC1* GA/AA (62 cases, 25 CRC-specific deaths).

Figure 3A




Fig. 3B




Fig. 3.
A) Location of the *ODC1* promoter SNP. The SNP under investigation in this study is 316 nucleotides 3' of the *ODC1* transcription start site (marked with an asterisk). This SNP resides between two consensus E-boxes as shown by the underlined sequences, and affects a *Pst*I restriction site, marked with a box. **B)** RFLP analysis of *ODC1* SNP. DNA was obtained from two cell types, and the region surrounding the *ODC1* SNP site was sequenced. Colon-derived HT29 cells were found to be heterozygous GA, while HCT116 cells were found to be homozygous GG, at the *ODC1* SNP locus. A 350 bp PCR product of this region was obtained

from each cell type and subjected to digestion with PstI. Evidence of an A-allele was indicated by restriction products smaller than 350 bp.

Fig. 4A




Fig. 4B




Fig. 4.
A) E-box protein expression in colon-derived cells. Expression of proteins to be evaluated for binding to the +316 *ODCI* SNP was assessed by Western blot analysis. Extracts of both HT29 and HCT116 cells were evaluated for c-MYC, MAD1 and MAD4; β -actin was used as a loading control. **B)** Documentation of allele-specific transcription factor binding by chromatin immunoprecipitation (CHIP) analysis. CHIP analysis was conducted as described in Material and Methods. HT29 cells were a source of *ODCI* A-alleles, as these cells are heterozygous GA at this site. HCT116 cells were used as a source of *ODCI* G-alleles.

Figure 5A




Figure 5B




Fig. 5.

A) Effect of *c-MYC* expression on *ODC1* allele-specific promoter activity in HT29 colon derived cells. Promoter activity was measured after transfection with *ODC1* promoter reporter plasmids co-transfected with pcDNA 3.0 plasmid (□) or CMV-*MYC* expression vector (■). Promoter constructs differ by the presence of the first E-box element, located in -485 to -480 bp (“wt E-box1” for the wild-type sequence or “mut E-box1”, for a mutant sequence). The constructs differ also by the *ODC1* +316 SNP (“+316 G” or “+316 A”). *, $P \leq 0.013$ for each of the four comparisons relative to promoter activity with pcDNA 3.0 co-transfection. **B)** Effect of *MAD1* expression on *ODC1* allele-specific promoter activity in HT29 colon tumor derived cells. Promoter activity was measured after transfection with *ODC1* promoter reporter plasmids co-transfected with pcDNA 3.1 plasmid (□) or with a pCDNA-*MAD1* plasmid (■). Promoter constructs used were described in the legend for panel A of this figure. *, $P = 0.027$, statistical significance relative to promoter activity with pcDNA 3.1 co-transfection.

Table 1

Descriptive analysis for colorectal cancer cases overall and based on *ODCI* genotype

	All CRC Cases n = 400	<i>ODCI</i> GG n = 208	<i>ODCI</i> GA/AA n = 192	P-value	
Median Age (with age range)	56.6 (29-89)	56.8 (29-89)	56.4 (29-82)	0.24	
Gender					
Male	230 (58%)	117 (56%)	113 (59%)	0.60	
Female	170 (41%)	91 (44%)	79 (41%)		
Ethnicity					
Non-Hispanic Caucasian	351 (88%)	188 (90%)	163 (85%)	0.14	
African American	4 (1%)	2 (1%)	2 (1%)		
Caucasian-Hispanic	20 (5%)	11 (5%)	9 (5%)		
Asian	23 (6%)	7 (3%)	16 (8%)		
Other	2 (<1%)	0 (0%)	2 (1%)		
Family History of CRC					
Yes	106 (26%)	56 (27%)	50 (26%)	0.84	
No	294 (74%)	152 (73%)	142 (74%)		
Stage at Diagnosis					
I	146 (37%)	72 (35%)	74 (39%)	0.49	
II	128 (32%)	72 (35%)	56 (29%)		
III	126 (31%)	64 (31%)	62 (32%)		
Colon/Rectum Site					
Proximal and transverse	120 (30%)	65 (31%)	55 (29%)	0.90	
Descending	22 (6%)	12 (6%)	10 (5%)		
Sigmoid	110 (28%)	55 (26%)	55 (29%)		
Rectosigmoid	57 (14%)	32 (15%)	25 (13%)		
Mid-Low Rectum	86 (22%)	41 (20%)	45 (23%)		
Colorectum, unspecified	5 (1%)	3 (1%)	2 (1%)		
Histologic Subtype					
Adenocarcinoma Mucinous	364 (91%)	183 (88%)	181 (94%)		0.16
adenocarcinoma	26 (7%)	18 (9%)	8 (4%)		
Carcinoma	9 (2%)	6 (3%)	3 (2%)		
NOS	1 (<1%)	1 (<1%)	0 (0%)		
Tumor Grade					
I	62 (17%)	27 (14%)	35 (20%)	0.36	
II	261 (71%)	140 (73%)	121 (68%)		
III	46 (13%)	24 (13%)	22 (12%)		
No. missing	31	17	14		
Surgical Treatment					
Yes	395 (99%)	204 (98%)	191 (99%)	0.21	
No	5 (1%)	4 (2%)	1 (1%)		
Radiation Therapy					
Yes	63 (16%)	29 (14%)	34 (18%)	0.30	
No	337 (84%)	179 (86%)	158 (82%)		
Chemotherapy					
Yes	170 (45%)	84 (44%)	86 (46%)	0.56	
No	208 (55%)	109 (56%)	99 (54%)		
No. missing	22	15	7		

Table 2Multivariate overall survival and CRC-specific survival analysis for CRC cases based on *ODCI* genotype.

	<i>ODCI</i> Genotype		<i>P</i> -value
	GG	GA/AA	
Overall Mortality			
Number of events	47	62	
Number at risk	208	192	
Unadjusted HR (95% CI)	1 (Reference)	1.57 (1.07-2.29)	0.020
Adjusted HR (95% CI)*	1 (Reference)	1.58 (1.07-2.34)	0.021
CRC-Specific Mortality			
Number of events	22	37	
Number at risk	208	192	
Unadjusted HR (95% CI)	1 (Reference)	1.97 (1.16-3.34)	0.012
Adjusted HR (95% CI)*	1 (Reference)	2.02 (1.17-3.50)	0.012

* Includes stratification for stage (I, II, III) and adjustment for age (years), gender, ethnicity, family history of CRC, TNM stage at diagnosis, tumor site within the colorectum, histologic subtype, treatment with surgery, radiation therapy, and chemotherapy.